Search for content, post, videos

Renal Disease Drug Nails Trial

The NEFIGAN Trial of Pharmalink AB’s Nefecon®, a drug for the treatment of primary IgA nephropathy, was stopped early because the drug fully met its primary efficacy endpoint at a planned interim analysis, according to news from  The interim analysis, conducted by the Data &
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.